Can ivermectin be used to treat scalp ringworm (tinea capitis)?

Ivermectin Should NOT Be Used for Scalp Ringworm

Ivermectin is not an appropriate treatment for tinea capitis (scalp ringworm) and is not recommended in any established guidelines for this condition. The established first-line treatments are oral griseofulvin or terbinafine, with the choice depending on the causative organism 1.

Why Ivermectin Is Not Indicated

FDA-Approved Indications

Ivermectin is FDA-approved only for parasitic infections, specifically:

• Intestinal strongyloidiasis
• Onchocerciasis (river blindness) 2

The drug has no antifungal activity against dermatophytes that cause tinea capitis 2. Ivermectin works by binding to glutamate-gated chloride channels in invertebrate parasites, causing paralysis and death of the parasite—a mechanism completely irrelevant to fungal infections 2.

Evidence Base

While ivermectin has been studied for head lice (pediculosis capitis) 3, 4, 5, there is no evidence supporting its use for fungal scalp infections. The research evidence provided relates exclusively to parasitic infestations, not dermatophyte infections 3, 4.

Correct Treatment Approach for Tinea Capitis

First-Line Systemic Therapy

Oral antifungal therapy is mandatory—topical therapy alone is insufficient because it cannot penetrate the hair shaft and follicle 1.

Treatment selection depends on the causative organism:

• For Trichophyton species (T. tonsurans, T. violaceum, T. soudanense):

  • Terbinafine is more efficacious 1
  • Dosing by weight: <20 kg: 62.5 mg/day; 20-40 kg: 125 mg/day; >40 kg: 250 mg/day for 2-4 weeks 1

• For Microsporum species (M. canis, M. audouinii):

  • Griseofulvin is more effective 1
  • Dosing: <50 kg: 15-20 mg/kg/day for 6-8 weeks; >50 kg: 1 g/day for 6-8 weeks 1
  • Griseofulvin shows 88.5% response rates for Microsporum vs. only 67.9% for Trichophyton 1

Why Species Matters

Terbinafine fails against Microsporum because its minimum inhibitory concentration exceeds the maximum concentration achievable in hair, and it is not excreted in sweat or sebum of prepubertal children, preventing it from reaching the scalp surface where Microsporum arthroconidia are located 1.

Second-Line Therapy

If first-line treatment fails:

• Itraconazole 50-100 mg/day for 4 weeks or 5 mg/kg/day for 2-4 weeks 1
• Itraconazole has activity against both Trichophyton and Microsporum species 1

Alternative Agents for Refractory Cases

For exceptional circumstances when standard therapies fail:

• Fluconazole (though not licensed for tinea capitis in children <10 years in the UK) 1
• Voriconazole (limited by cost and licensing restrictions) 1

Critical Clinical Pitfalls

Common Mistakes to Avoid

1. Using topical therapy alone—this will fail because it cannot reach the hair follicle 1
2. Delaying treatment while awaiting culture—if kerion or cardinal signs (scale, lymphadenopathy, alopecia) are present, start empiric therapy immediately 1
3. Stopping treatment based on clinical improvement alone—the endpoint is mycological cure, not clinical cure; repeat mycology sampling until clearance is achieved 1
4. Using the wrong drug for the organism—terbinafine for Microsporum or griseofulvin for Trichophyton will result in treatment failure 1

Treatment Failure Management

If treatment fails, consider:

• Non-compliance
• Suboptimal drug absorption
• Reinfection
• Wrong organism identification 1

Continue current therapy for an additional 2-4 weeks if there is clinical improvement but ongoing positive mycology 1. If no initial clinical improvement, switch to second-line therapy 1.

Adjunctive Measures

• Antifungal shampoos (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) reduce spore transmission but are not curative 1
• Screen household contacts for T. tonsurans cases, as >50% of family members may be affected 1
• Children on appropriate therapy should be allowed to attend school 1